ReviewNeuro-oncology2016
A malignant cellular network in gliomas: potential clinical implications.
Review in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 110 citations in OpenAlex.
- Actin, connexin-43 and GAP-43 expression in gliomas: real-world associations with IDH status, tumor burden and survival.Journal of neuro-oncology · 2026Article
- Mitochondria transfer in glioblastoma.Neuro-oncology · 2026Review
- Targeting Tumour Microtubes to Disrupt Glioma Networks.Research square · 2026Article
- Multiscale network perspectives on glioma: from tumour biology to symptoms, survival and treatment.Nature reviews. Neurology · 2026Review
- Mitochondrial transfer in solid tumors: dual roles in tumor progression and therapeutic targeting.Extracellular vesicles and circulating nucleic acids · 2026Review
- Nano- and Microtubes: Tiny Fusion Events but Not Overall Plasma Membrane Merger for Exchanging Intracellular Components.Advances in experimental medicine and biology · 2026Review
- Glioblastoma tumor microtubes and brain fatty acid-binding protein: Path to directional infiltration.Neuro-oncology · 2025Article
- Cancer Neuroscience: Decoding Neural Circuitry in Tumor Evolution for Targeted Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Innovative Therapeutic Strategies Targeting the Network Architecture of Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- Morphoregulatory ADD3 underlies glioblastoma growth and formation of tumor-tumor connections.Life science alliance · 2025Article
- Denoising strategies of functional connectivity MRI data in lesional and non-lesional brain diseases.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- The Alcatraz-Strategy: a roadmap to break the connectivity barrier in malignant brain tumours.Molecular oncology · 2024Review
- Potential Mechanism and Involvement of p120-Catenin in the Malignant Biology of Glioma.Journal of Korean Neurosurgical Society · 2024Article
- Disrupting glioblastoma networks with tumor treating fields (TTFields) in in vitro models.Journal of neuro-oncology · 2024Article
- Review
- A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1.Nature communications · 2024Article
- Tunneling Nanotubes: Implications for Chemoresistance.Results and problems in cell differentiation · 2024Review
- Integrating and optimizing tonabersat in standard glioblastoma therapy: A preclinical study.PloS one · 2024Article
- Article
- Sialic acid metabolism orchestrates transcellular connectivity and signaling in glioblastoma.Neuro-oncology · 2023Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent discovery of distinct, ultra-long, and highly functional membrane protrusions in gliomas, particularly in astrocytomas, extends our understanding of how these tumors progress in the brain and how they resist therapies. In this article, we will focus on ideas on how to target these membrane protrusions, for which we have suggested the term "tumor microtubes" (TMs), and the malignant multicellular network they form. First, we discuss TM-specific features and their differential biological functions known so far. Second, the connection between 1p/19q codeletion and the inability to form functional TMs via certain neurodevelopmental pathways is presented; this could provide an explanation for the distinct clinical features of oligodendrogliomas. Third, the role of TMs for primary and potentially also adaptive resistance to cytotoxic therapies is highlighted. Fourth, avenues for therapeutic approaches to inhibit TM formation and/or function are discussed, with a focus on disruption (or exploitation) of network functionality. Finally, we propose ideas on how to use TMs as a biomarker in glioma patients. An increasing understanding of TMs in clinical and preclinical settings will show us whether they really are a long-sought-after Achilles' heel of treatment-resistant gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.